News
Novo Nordisk shares extend losses, erasing nearly all gains since Wegovy launch
Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to wipe out almost all the gains made since the drugmaker launched its blockbuster weight-loss treatment Wegovy.
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.
Danish leader will face a challenging landscape among competitors ...
We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer ...
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
COPENHAGEN (Reuters) - Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and ...
The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback